Drug maker OBI Pharma Inc (台灣浩鼎) yesterday said that it will start generating revenue this year, driven by the planned launch of its DIFCID antibiotic in Taiwan by the end of the second quarter.
The company has failed to post revenue since 2011, before its started trading its shares on the Emerging Stock Market in 2012.
“We are currently finalizing talks with the National Health Insurance Administration concerning drug prices, as well as with our suppliers regarding materials prices,” general manager Amy Huang (黃秀美) said.
However, Huang said that the market for DIFCID in Taiwan is small because antibiotics are not overused in the nation and it is not in need of new kinds of antibiotics.
The company could continue its loss-making streak this year, since it is expected to spend between NT$600 million and NT$700 million (US$19.77 million and US$49 million) on research and development. OBI Pharma said that most of the amount will be used to finance clinical trials for its drugs.
In the first half of last year, the company spent NT$177.82 million on research and development, according to its stock exchange filing.
Over the same period, OBI Pharma reported NT$202.47 million in losses, an increase from the NT$101.03 million in losses it posted a year ago that was the result of more spending on research and development, its filing showed.
The construction of Amaran Biotechnology Inc’s (潤雅生技) new factory in the Hsinchu Biomedical Science Park (新竹生醫園區) will be operational at the end of this year after the factory receives Good Manufacturing Practice its (GMP) certificate from the government, Huang said, adding that the factory will make botox for OBI Pharma.
According to Huang, the company will complete data collection for phase-three clinical trails for OBI-822, which is used to treat breast cancer, in Taiwan by the end of June.
The company plans to file for a permit to sell OBI-822 in Taiwan in 2016 and in the US in 2018, it said.
The firm is to launch the cancer drug in the US, Taiwan and China on its own, but is seeking partners to sell the medication in Europe and Japan, it said.
OBI Pharma also acquired a new monoclonal antibody to treat cancer last year from Academia Sinica, Huang said, adding that the drug is in the pre-clinical trial stage.
It also has plans to shift to the GRETAI Securities Market by the end of this year.
OBI Pharma stock fell 1.51 percent to NT$227.94 yesterday on the Emerging Stock Market.
Taiwan’s foreign exchange reserves fell below the US$600 billion mark at the end of last month, with the central bank reporting a total of US$596.89 billion — a decline of US$8.6 billion from February — ending a three-month streak of increases. The central bank attributed the drop to a combination of factors such as outflows by foreign institutional investors, currency fluctuations and its own market interventions. “The large-scale outflows disrupted the balance of supply and demand in the foreign exchange market, prompting the central bank to intervene repeatedly by selling US dollars to stabilize the local currency,” Department of Foreign
ENERGY ISSUES: The TSIA urged the government to increase natural gas and helium reserves to reduce the impact of the Middle East war on semiconductor supply stability Chip testing and packaging service provider ASE Technology Holding Co (日月光投控) yesterday said it planned to invest more than NT$100 billion (US$3.15 billion) in building a new advanced chip testing facility in Kaohsiung to keep up with customer demand driven by the artificial intelligence (AI) boom. That would be included in the company’s capital expenditure budget next year, ASE said. There is also room to raise this year’s capital spending budget from a record-high US$7 billion estimated three months ago, it added. ASE would have six factories under construction this year, another record-breaking number, ASE chief operating officer Tien Wu
The EU and US are nearing an agreement to coordinate on producing and securing critical minerals, part of a push to break reliance on Chinese supplies. The potential deal would create incentives, such as minimum prices, that could advantage non-Chinese suppliers, according to a draft of an “action plan” seen by Bloomberg. The EU and US would also cooperate on standards, investments and joint projects, as well as coordinate on any supply disruptions by countries like China. The two sides are additionally seeking other “like-minded partners” to join a multicountry accord to help create these new critical mineral supply chains, which feed into
For weeks now, the global tech industry has been waiting for a major artificial intelligence (AI) launch from DeepSeek (深度求索), seen as a benchmark for China’s progress in the fast-moving field. More than a year has passed since the start-up put Chinese AI on the map in early last year with a low-cost chatbot that performed at a similar level to US rivals. However, despite reports and rumors about its imminent release, DeepSeek’s next-generation “V4” model is nowhere in sight. Speculation is also swirling over the geopolitical implications of which computer chips were chosen to train and power the new
RSS